AnaptysBio (ANAB) Stock Price, Quote, News & History | Benzinga

SPY770.32+0.09%QQQ724.33−0.63%BTC/USD82,021.68−0.13%DIA520.66+0.98%GLD381.10+1.36%TLT80.26+1.73%

AnaptysBio Inc (ANAB) Stock Price, Quote, News & History

ANABNASDAQ

Trade with Public

Trade with Public

$48.71

2.044.37%

Last update: Oct 15, 4:00 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$47.43

Close

$48.71

Volume / Avg.

411.11K / 562.16K

Day Range

$48.71 - $48.71

52 Wk Range

30.27 - 73.30

Market Cap

$1.36B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

38

Short Interest

38.53%

Days to Cover

8.19

Recent AnaptysBio, Inc. News

FedEx, Cerebras Systems And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

U.S. stock futures mixed, Nasdaq 100 up 100 points. FedEx falls after Q4 results, beating estimates but reporting reduced operating margin. Other stocks also down in pre-market.

Avi Kapoor

AnaptysBio Stock Rallies As Delaware Court Tosses Tesaro Breach Claim

AnaptysBio shares jump 12% after a favorable Delaware Court ruling in the Tesaro dispute. See the latest technical outlook and more.

Vandana Singh

XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday

U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acquire XOMA for $39.00/share. Other big gainers: MANE, ORKA, OGN, XE, PLBL, SLS, ANAB, EVH, IHRT, RPAY, JBIO, BEAM.

Avi Kapoor

AnaptysBio Pushes Back Against Lawsuit Over Cancer Drug Jemperli Royalties

AnaptysBio asks a Delaware court to dismiss Tesaro's breach claim, citing anti-SLAPP law in a dispute over Jemperli royalties and licensing rights.

Vandana Singh

GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties

GSK's Tesaro sues AnaptysBio over alleged Jemperli contract breaches, putting royalties, milestones, and future licensing rights into question.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

4.48M

Investing Cash Flow (TTM)

248.17M

Financing Cash Flow (TTM)

-102.81M

Free Cash Flow (TTM)

4.41M

Capital Expenditure (TTM)

-69.00K

Net Change in Cash (TTM)

149.83M

Analyst Trends and Forecast

3

Apr

3

May

1

Jun

2

Aug

3

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.24B

PE Ratio (TTM)

-

PE Ratio (FWD)

19.27

PEG Ratio (TTM)

-

PS Ratio (TTM)

5.68

PB Ratio (TTM)

131.81

Earnings Yield % (TTM)

-2.19%

Earnings Yield % (FWD)

5.19%

EV / EBITDA (TTM)

21.27

Price / EBITDA (TTM)

22.56

Price / Free Cash Flow (TTM)

299.24

Book Value / Share

$0.35

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$248.47M

Debt to Equity

1.07

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-